Product
HuMax-CD4
Aliases
Zanolimumab
4 clinical trials
3 indications
Indication
T-Cell LymphomaIndication
Cutaneous T-Cell LymphomaIndication
Rheumatoid ArthritisClinical trial
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell LymphomaStatus: Completed, Estimated PCD: 2006-01-01
Clinical trial
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Advanced Stage (IIA-IVB) Cutaneous T-cell LymphomaStatus: Completed, Estimated PCD: 2004-06-29
Clinical trial
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Persistent Early Stage (IA-IIA) Cutaneous T-Cell LymphomaStatus: Completed, Estimated PCD: 2004-05-05
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active Rheumatoid Arthritis Failing Treatment With Methotrexate and TNF-alpha Blocking AgentsStatus: Terminated, Estimated PCD: 2003-03-31